Impact of Pharmacogenetics on High-Dose Methotrexate Toxicity in Pediatric Oncology

<b>Background</b>: Childhood cancers represent a heterogeneous group of malignancies and remain one of the leading causes of mortality among children under 14 years of age, ranking second only to accidental injuries, and fourth among individuals aged 15 to 19 years. Despite notable impro...

Full description

Bibliographic Details

Published in:	Pharmaceutics
Main Authors:	Luciana Maria Marangoni-Iglecias, Almudena Sánchez-Martin, Laura Elena Pineda-Lancheros, Yasmín Cura, Noelia Marquez-Pete, José María Gálvez-Navas, Nerea Báez-Gutiérrez, Adrián Manuel de La Jara-Vera, Emilia Urrutia-Maldonado, Cristina Pérez-Ramírez, Alberto Jiménez-Morales
Format:	Article
Language:	English
Published:	MDPI AG 2025-04-01
Subjects:	HDMTX genetic polymorphisms childhood cancer pharmacogenetics
Online Access:	https://www.mdpi.com/1999-4923/17/5/585